Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Depreciation and Depletion: 2020-2024

Historic Depreciation and Depletion for Entrada Therapeutics (TRDA) over the last 5 years, with Dec 2024 value amounting to $3.8 million.

  • Entrada Therapeutics' Depreciation and Depletion rose 33.33% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 22.36%. This contributed to the annual value of $3.8 million for FY2024, which is 33.76% up from last year.
  • Entrada Therapeutics' Depreciation and Depletion amounted to $3.8 million in FY2024, which was up 33.76% from $2.8 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Depreciation and Depletion registered a high of $3.8 million during FY2024, and its lowest value of $326,000 during FY2020.
  • Moreover, its 3-year median value for Depreciation and Depletion was $2.8 million (2023), whereas its average is $2.8 million.
  • Data for Entrada Therapeutics' Depreciation and Depletion shows a peak YoY surged of 242.64% (in 2021) over the last 5 years.
  • Entrada Therapeutics' Depreciation and Depletion (Yearly) stood at $326,000 in 2020, then soared by 242.64% to $1.1 million in 2021, then soared by 70.10% to $1.9 million in 2022, then surged by 49.53% to $2.8 million in 2023, then spiked by 33.76% to $3.8 million in 2024.